Table 1.

qPCR validation of microarray data

				Fold Change
Treatment	Gene	Assay	Effect of Treatment	3d WT	3d KO	14d WT	14d KO
DEN	TRIM63	qPCR	U	3.88	ND	(−)1.2	ND
		array	U	3.05	ND	(−)1.2	ND
	MYOG	qPCR	U	44.9	35.5	21.6	15.1
		array	U	>300*	16.0	16.5	14.6
	MYBPC2	qPCR	D	2.72	1.38	21.0	10.1
		array	D	1.94	1.05	4.0	1.34
DEX	ARRDC2	qPCR	U	3.40	2.25	5.02	0.88
		array	U	2.38	1.34	5.23	1.54
	MT2	qPCR	U	7.96	6.91	2.46	3.19
		array	U	2.64	2.99	3.66	3.45
	COL1A1	qPCR	D	4.71	6.66	6.74	6.81
		array	D	7.76	9.39	11.53	9.11

qPCR, quantitative PCR; DEN, denervation; DEX, dexamethasone; WT, wild type; KO, knockout; U, the gene was upregulated; D, the gene was downregulated; ND, not determined.

TRIM63, MuRF1; MYOG, myogenin; MYBPC2, myosin binding protein C2; ARRDC2, arrestin domain containing 2; MT2, metallothionein 2; COL1A1, collagen 1α1.

^*Fold induction of myogenin is likely inaccurate since basal expression in the 3 day (d) control animals was below baseline. (−) in the 14d WT MuRF1 DEN data indicates that the gene was slightly downregulated relative to controls after being strongly upregulated at 3d.